Deal Announcements

Apexigen Secures $15 Million New Venture Capital

Thursday, May 16, 2013 5:56:00 AM PDT | VentureDeal

   Burlingame, CA  --  Biotechnology company Apexigen has sold $15 million in equity stock, according to an SEC filing.

Apexigen is developing antibody product candidates that it believes will be able to impact previously inaccessible disease mechanisms.

Investors in the financing were not disclosed.

Apexigen is still seeking $5 million in additional financing, according to the filing.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1